How Lurbinectedin's Mechanism Works
Lurbinectedin binds covalently to DNA minor grooves, particularly at GC-rich regions, forming monoadducts that stall RNA polymerase II. This triggers polymerase trapping, DNA breaks, and activation of the DNA damage response, leading to cancer cell death. It selectively targets malignant cells by degrading transcription factors and enhancers in tumor-specific open chromatin, sparing normal cells with less active transcription.[1][2]
Why It Targets Small Cell Lung Cancer Specifically
In small cell lung cancer (SCLC), lurbinectedin's action concentrates on MYC family amplification sites and super-enhancers driving oncogenes like SOX2 and ASCL1. SCLC tumors rely heavily on these transcriptionally active regions, amplifying DNA damage there, while normal lung cells lack this dependency. Clinical approval for metastatic SCLC reflects this selectivity, shown in trials where it achieved 35% overall response rate post-platinum failure.[2][3]
How It Differs from Other Chemotherapy Agents
Unlike platinum drugs (e.g., cisplatin), which cause broad DNA crosslinks, lurbinectedin's covalent binding and polymerase II eviction create transcription-specific damage. Compared to topoisomerase inhibitors like irinotecan, it avoids topo-DNA cleavage complexes, reducing some off-target effects. This explains its activity in platinum-resistant SCLC, where it restores sensitivity indirectly via nucleotide excision repair inhibition.[1][4]
What Happens in Resistant or Other Cancers
Resistance emerges via enhanced DNA repair (e.g., NER pathway upregulation) or SLFN11 inactivation, limiting efficacy. Trials test it in pleural mesothelioma, endometrial, and head/neck cancers, but responses are lower outside SCLC due to weaker enhancer dependency. Combination with doxorubicin exploits synergies in transcription blockade.[2][5]
Clinical Evidence on Targeting Selectivity
Phase II trials (e.g., ATLANTIS) confirmed SCLC selectivity, with tumor regression tied to high SLFN11 expression—a sensor of replication stress lurbinectedin induces. Preclinical models show 10-fold greater potency in MYC-amplified cells versus normal fibroblasts.[3][6]
[1]: FDA Label for Zepzelca (lurbinectedin)
[2]: Nature Reviews Drug Discovery: Lurbinectedin mechanism
[3]: JAMA Oncology: Lurbinecteddin in SCLC
[4]: Cancer Discovery: Transcriptional selectivity
[5]: ClinicalTrials.gov: Ongoing lurbinecteddin trials
[6]: Science Translational Medicine: SLFN11 role